Emerging Treatments in the Ongoing Battle Against Community-Acquired Bacterial Pneumonia: The Positive Impact of Online Education

SIMI T. HURST, PHD; SUSAN L. SMITH, PHD, Medscape, LLC, New York, NY, USA

BACKGROUND
Community-acquired pneumonia (CAP) remains one of the most significant causes of morbidity and mortality in the world. Estimates of the incidence of community-acquired bacterial pneumonia (CAPB) range from 4 to 5 million cases annually, with about 25% requiring hospitalization. To address the growing tide of antibiotic resistance, several new agents are in development for the treatment of CAPB. A key goal of this study was to use continuing medical education (CME) to improve infectious disease (ID) specialists’ knowledge and confidence with respect to identifying distinguishing characteristics among emerging CAPB treatments.

METHODS
A total of 3,856 physicians, along with 9,826 healthcare providers, have participated as of August 25, 2018.

RESULTS
76% of ID specialists indicated a commitment to incorporate one or more changes into practice.

REFERENCES